Clinical toxicology (Philadelphia, Pa.) · 2025
Outcomes of extra-dose exposures of Vaughan Williams Class I or III antidysrhythmic medications.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alsakha Ahmed, Bukowiecki Brenda, Marraffa Jeanna M, Calleo Vince, Keenan Michael
Аннотация
INTRODUCTION: Antidysrhythmic medications are commonly prescribed, but there is little information on the incidence of adverse effects following an inadvertent extra dose of these medications. This poses a challenge to poison centers when trying to decide which patients need to be sent to a healthcare facility for monitoring.
METHODS: A retrospective data review of cases reported to a regional poison center between January 1, 2012 and December 31, 2022 was performed. Cases were included if the exposure was a double dose or less of the patient's own antidysrhythmic medication, the exposure was unintentional or a result of therapeutic error, and the antidysrhythmic(s) belonged to Vaughan Williams Class I or III. Cases were included even if other medications were included in the therapeutic error. Descriptive data were collected on cases meeting the inclusion criteria.
RESULTS: One hundred and sixty-two exposures were included. Of these, only 49 were monitored in a healthcare facility for which coded outcomes were available. Of these, the majority had no or minor effects (83.7%). Two of the exposures developed hypotension, but both also involved either a beta-adrenoceptor blocking drug or a calcium-channel blocker. Of the 25 cases that only included an antidysrhythmic, adverse effects were even less common, with 92.0% having no or only minor effects.
DISCUSSION: In this small cohort, adverse events were uncommon with inadvertent extra dose antidysrhythmic exposures. However, serious outcomes have been reported in other studies. It appears adverse events are less common if the extra dose exposure does not involve other cardioactive medications.
CONCLUSIONS: Extra-dose exposures of some antidysrhythmics belonging to Vaughan Williams Class I or III were generally well tolerated, but more data are needed to determine whether certain patients can be safely monitored at home. For example, only three cases involved Class IA drugs. Based on our findings, patients who reportedly ingest an extra dose of an antidysrhythmic plus another cardioactive medication should be evaluated at a healthcare facility.
METHODS: A retrospective data review of cases reported to a regional poison center between January 1, 2012 and December 31, 2022 was performed. Cases were included if the exposure was a double dose or less of the patient's own antidysrhythmic medication, the exposure was unintentional or a result of therapeutic error, and the antidysrhythmic(s) belonged to Vaughan Williams Class I or III. Cases were included even if other medications were included in the therapeutic error. Descriptive data were collected on cases meeting the inclusion criteria.
RESULTS: One hundred and sixty-two exposures were included. Of these, only 49 were monitored in a healthcare facility for which coded outcomes were available. Of these, the majority had no or minor effects (83.7%). Two of the exposures developed hypotension, but both also involved either a beta-adrenoceptor blocking drug or a calcium-channel blocker. Of the 25 cases that only included an antidysrhythmic, adverse effects were even less common, with 92.0% having no or only minor effects.
DISCUSSION: In this small cohort, adverse events were uncommon with inadvertent extra dose antidysrhythmic exposures. However, serious outcomes have been reported in other studies. It appears adverse events are less common if the extra dose exposure does not involve other cardioactive medications.
CONCLUSIONS: Extra-dose exposures of some antidysrhythmics belonging to Vaughan Williams Class I or III were generally well tolerated, but more data are needed to determine whether certain patients can be safely monitored at home. For example, only three cases involved Class IA drugs. Based on our findings, patients who reportedly ingest an extra dose of an antidysrhythmic plus another cardioactive medication should be evaluated at a healthcare facility.